4-phenylbutyric acid has been researched along with Glioma in 4 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study we show that the chemical chaperone, glycerol, and the transcriptional regulator, sodium 4-phenylbutyrate, inhibit the constitutively activated inward current and reduce cell growth and migration in glioblastoma multiforme." | 7.73 | Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. ( Benos, DJ; Bubien, JK; Colby, G; Esimai, O; Fuller, CM; Gillespie, GY; Jovov, B; Kovacs, GG; Mapstone, TB; Markert, JM; Pahwa, AK; Vila-Carriles, WH; Zhou, ZH, 2006) |
| " In this study we show that the chemical chaperone, glycerol, and the transcriptional regulator, sodium 4-phenylbutyrate, inhibit the constitutively activated inward current and reduce cell growth and migration in glioblastoma multiforme." | 3.73 | Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. ( Benos, DJ; Bubien, JK; Colby, G; Esimai, O; Fuller, CM; Gillespie, GY; Jovov, B; Kovacs, GG; Mapstone, TB; Markert, JM; Pahwa, AK; Vila-Carriles, WH; Zhou, ZH, 2006) |
| " Enthusiasm is lent to this approach by the ability of AN-113 to efficiently kill glioma cells, its bioavailability and potency when administered orally, its capacity to cross the blood-brain barrier, and its effectiveness in combination with radiation." | 1.34 | AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. ( Entin-Meer, M; Haas-Kogan, DA; Nudelman, A; Rephaeli, A; Yang, X, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sozio, P | 1 |
| Fiorito, J | 1 |
| Di Giacomo, V | 1 |
| Di Stefano, A | 1 |
| Marinelli, L | 1 |
| Cacciatore, I | 1 |
| Cataldi, A | 1 |
| Pacella, S | 1 |
| Turkez, H | 1 |
| Parenti, C | 1 |
| Rescifina, A | 1 |
| Marrazzo, A | 1 |
| Baker, MJ | 1 |
| Brem, S | 1 |
| Daniels, S | 1 |
| Sherman, B | 1 |
| Phuphanich, S | 1 |
| Vila-Carriles, WH | 1 |
| Kovacs, GG | 1 |
| Jovov, B | 1 |
| Zhou, ZH | 1 |
| Pahwa, AK | 1 |
| Colby, G | 1 |
| Esimai, O | 1 |
| Gillespie, GY | 1 |
| Mapstone, TB | 1 |
| Markert, JM | 1 |
| Fuller, CM | 1 |
| Bubien, JK | 1 |
| Benos, DJ | 1 |
| Entin-Meer, M | 1 |
| Rephaeli, A | 1 |
| Yang, X | 1 |
| Nudelman, A | 2 |
| Haas-Kogan, DA | 1 |
4 other studies available for 4-phenylbutyric acid and Glioma
| Article | Year |
|---|---|
Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Drug Scr | 2015 |
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal | 2002 |
Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.
Topics: Acid Sensing Ion Channels; Amiloride; Antineoplastic Agents; Brain Neoplasms; Cell Membrane; Cell Mo | 2006 |
AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.
Topics: Antineoplastic Agents; Astrocytes; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prol | 2007 |